|
【结 构 式】 
|
【药物名称】 【化学名称】N-[4-[2(R)-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-ylmethyl]-1H-1,2,3-triazol-5-ylmethyl]-N,N-dimethylamine hydrochloride 【CA登记号】188923-01-5, 171242-11-8 (free base) 【 分 子 式 】C26H29ClF7N5O2 【 分 子 量 】611.99513 |
【开发单位】Merck & Co. (Originator) 【药理作用】Antidepressants, Mood Disorders, Treatment of, Nausea and Vomiting, Treatment of, NEUROLOGIC DRUGS, PSYCHOPHARMACOLOGIC DRUGS, Tachykinin NK1 Antagonists |
合成路线1
The first method required the chiral building block (S)-(4-fluorophenyl)glycine (VI), which was prepared from 4-fluorophenyl acetic acid (I) by two routes. Condensation of (I) with (S)-4-benzyl-2-oxazolidinone (II), via activation as the corresponding mixed anhydride with pivaloyl chloride, furnished the N-acyl oxazolidinone (III). The potassium enolate of (III) was then reacted with 2,4,6-triisopropylphenylsulfonyl azide, producing stereoselectively azide (IV). Hydrolytic removal of the chiral auxiliary of (IV) gave (S)-azido-(4-fluorophenyl)acetic acid (V), which was then reduced to the desired amino acid (VI) by catalytic hydrogenation over Pd/C. Alternatively, 4-fluorophenyl acetic acid (I) was converted to the corresponding acid chloride (VII) with SOCl2. Bromination of (VII) under Hell-Volhard-Zelinskii conditions, followed by quenching with MeOH, afforded the racemic alpha-bromo ester (VIII). Displacement of the bromide of (VIII) with NaN3 using a phase-transfer catalyst produced the azido ester (IX). Catalytic hydrogenation of the azido group of (IX) gave the racemic amino ester, which was resolved via formation of the diastereomeric salts with (+)-dibenzoyltartaric acid. The desired (S)-amino ester (X) was then hydrolyzed to (VI) under acidic conditions.
| 【1】 Baker, R.; Harrison, T.; Mcleod, A.M.; Owens, A.P.; Seward, E.M.; Swain, C.J.; Teall, M.R. (Merck Sharp & Dohme Ltd.); Substd. morpholine derivs. and their use as therapeutic agents. EP 0737192; EP 1099702; JP 1997507484; JP 2000219629; US 5612337; WO 9518124 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 18999 | 4-Fluorophenylacetic acid; 2-(4-Fluorophenyl)acetic acid | 405-50-5 | C8H7FO2 | 详情 | 详情 |
| (II) | 14694 | (S)-4-Benzyl-2-oxazolidinone; (4S)-4-Benzyl-1,3-oxazolan-2-one; (S)-(-)-4-Benzyl-2-oxazolidinone | 90719-32-7 | C10H11NO2 | 详情 | 详情 |
| (III) | 44186 | (4S)-4-benzyl-3-[2-(4-fluorophenyl)acetyl]-1,3-oxazolidin-2-one | C18H16FNO3 | 详情 | 详情 | |
| (IV) | 44188 | (4S)-3-[(2S)-2-azido-2-(4-fluorophenyl)ethanoyl]-4-benzyl-1,3-oxazolidin-2-one | C18H15FN4O3 | 详情 | 详情 | |
| (V) | 44189 | (2S)-2-azido-2-(4-fluorophenyl)ethanoic acid | C8H6FN3O2 | 详情 | 详情 | |
| (VI) | 37104 | (8R,9S,10R,13S,14S,17S)-17-hydroxy-2-[(Z)-hydroxymethylidene]-4,10,13,17-tetramethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one | C22H32O3 | 详情 | 详情 | |
| (VII) | 44191 | methyl 2-bromo-2-(4-fluorophenyl)acetate | C9H8BrFO2 | 详情 | 详情 | |
| (VIII) | 53260 | (1R,3S,5R)-3-{[tert-butyl(dimethyl)silyl]oxy}tricyclo[3.2.0.0~2,7~]heptan-6-one | n/a | C13H22O2Si | 详情 | 详情 |
| (IX) | 53261 | bicyclo[3.2.0]hept-2-en-6-one | 13173-09-6 | C7H8O | 详情 | 详情 |
| (X) | 43098 | (2R)-2-amino-2-(4-fluorophenyl)ethanoic acid | 7292-73-1 | C8H8FNO2 | 详情 | 详情 |
合成路线2
Reductive alkylation of (S)-(4-fluorophenyl)glycine (VI) with benzaldehyde and NaBH4 generated the N-benzyl amino acid (XI). This was cyclized with 1,2-dibromoethane (XII) to yield the morpholinone (XIII). Reduction of the lactone function of (XIII) with L-Selectride at -70 C, followed by acylation of the intermediate lactol (XIV) with 3,5-bis(trifluoromethyl)benzoyl chloride (XV), furnished the aroyloxy morpholine (XVI) as the main isomer. Ester (XVI) was converted to the enol ether (XVII) upon treatment with dimethyltitanocene, generated from titanocene dichloride and methyllithium. Catalytic hydrogenation of the enol ether double bond of (XVII) with simultaneous benzyl group hydrogenolysis generated the desired morpholine (XVIII) along with its diastereoisomer (XIX); these were separated by flash chromatography.
| 【1】 Baker, R.; Harrison, T.; Mcleod, A.M.; Owens, A.P.; Seward, E.M.; Swain, C.J.; Teall, M.R. (Merck Sharp & Dohme Ltd.); Substd. morpholine derivs. and their use as therapeutic agents. EP 0737192; EP 1099702; JP 1997507484; JP 2000219629; US 5612337; WO 9518124 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 43098 | (2R)-2-amino-2-(4-fluorophenyl)ethanoic acid | 7292-73-1 | C8H8FNO2 | 详情 | 详情 |
| (XI) | 44190 | (2S)-2-(benzylamino)-2-(4-fluorophenyl)ethanoic acid | C15H14FNO2 | 详情 | 详情 | |
| (XII) | 10252 | 1,2-Dibromoethane; Ethylene dibromide | 106-93-4 | C2H4Br2 | 详情 | 详情 |
| (XIII) | 18288 | (3S)-4-benzyl-3-(4-fluorophenyl)-2-morpholinone | C17H16FNO2 | 详情 | 详情 | |
| (XIV) | 18289 | (2S,3S)-4-benzyl-3-(4-fluorophenyl)-2-morpholinol | C17H18FNO2 | 详情 | 详情 | |
| (XV) | 18290 | 3,5-Bis(trifluoromethyl)benzoyl chloride | 785-56-8 | C9H3ClF6O | 详情 | 详情 |
| (XVI) | 18291 | (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholinyl 3,5-bis(trifluoromethyl)benzoate | C26H20F7NO3 | 详情 | 详情 | |
| (XVII) | 18292 | (2R,3S)-4-benzyl-2-([1-[3,5-bis(trifluoromethyl)phenyl]vinyl]oxy)-3-(4-fluorophenyl)morpholine; (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholinyl 1-[3,5-bis(trifluoromethyl)phenyl]vinyl ether | C27H22F7NO2 | 详情 | 详情 | |
| (XVIII) | 18293 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-([(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholine | 171482-05-6 | C20H18F7NO2 | 详情 | 详情 |
| (XIX) | 53292 | (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-({(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)morpholine | n/a | C20H18F7NO2 | 详情 | 详情 |
合成路线3
In an alternative route to morpholine (XVIII), bromination of 1,3-bis(trifluoromethyl)benzene (XX) by means of 1,3-dibromo-5,5-dimethylhydantoin (XXI) yielded bromide (XXII). The Grignard reagent prepared from aryl bromide (XXII) was acylated with acetic anhydride at -15 C to produce acetophenone (XXIII). Enantioselective reduction of ketone (XXIII) with ruthenium(II) chloride in the presence of (1S,2R)-cis-1-amino-2-indanol furnished the (R)-alcohol (XXIV). N-Benzyl ethanolamine (XXV) was condensed with glyoxylic acid (XXVI) to give the hydroxy oxazinone (XXVII). This was coupled with the chiral alcohol (XXIV) using trifluoroacetic anhydride and boron trifluoride etherate to afford the target (R,R)-adduct (XXVIII) as the main diastereoisomer. Addition of 4-fluorophenylmagnesium bromide (XXIX) to the lactam function of (XXVIII), followed by catalytic hydrogenation of the intermediate (XXX), provided the required disubstituted morpholine (XVIII).
| 【1】 Wang, J.; Crocker, L.; Cai, D. (Merck & Co., Inc.); Polymorphic form of a tachykinin receptor antagonist. WO 0132656 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVIII) | 18293 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-([(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholine | 171482-05-6 | C20H18F7NO2 | 详情 | 详情 |
| (XX) | 53293 | 1,3-Bis(trifluoromethyl)benzene; 1,3-Di(trifluoromethyl)benzene; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-m-xylene; m-Xylene hexafluoride | 402-31-3 | C8H4F6 | 详情 | 详情 |
| (XXI) | 31277 | 1,3-dibromo-5,5-dimethyl-2,4-imidazolidinedione | 77-48-5 | C5H6Br2N2O2 | 详情 | 详情 |
| (XXII) | 53294 | 1,3-Bis(trifluoromethyl)-5-bromobenzene; 1-Bromo-3,5-bis(trifluoromethyl)benzene; 3,5-Bis(trifluoromethyl)bromobenzene | 328-70-1 | C8H3BrF6 | 详情 | 详情 |
| (XXIII) | 40778 | 1-[3,5-bis(trifluoromethyl)phenyl]-1-ethanone | 30071-93-3 | C10H6F6O | 详情 | 详情 |
| (XXIV) | 53295 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]-1-ethanol | n/a | C10H8F6O | 详情 | 详情 |
| (XXV) | 53296 | 4-benzyl-2-hydroxy-3-morpholinone | 287930-73-8 | C11H13NO3 | 详情 | 详情 |
| (XXVI) | 15618 | 2-Oxoacetic acid; Glyoxylic Acid | 298-12-4 | C2H2O3 | 详情 | 详情 |
| (XXVII) | 25630 | 2-(benzylamino)-1-ethanol | 104-63-2 | C9H13NO | 详情 | 详情 |
| (XXVIII) | 53297 | (2R)-4-benzyl-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-morpholinone | n/a | C21H19F6NO3 | 详情 | 详情 |
| (XXIX) | 13643 | 4-fluorophenyl magnesium bromide;Bromo(4-fluorophenyl)magnesium;bromo(p-fluorophenyl)Magnesium;p-Fluorophenylmagnesium bromide | 352-13-6 | C6H4BrFMg | 详情 | 详情 |
| (XXX) | 53298 | (2R)-4-benzyl-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)-3-morpholinol | n/a | C27H24F7NO3 | 详情 | 详情 |
合成路线4
From the intermediate morpholine (XVIII) the title compound was obtained by several routes. Alkylation of (XVIII) with propargyl bromide (XXXI) gave the N-propargyl morpholine (XXXII). Palladium-catalyzed addition of N,N-dimethylcarbamoyl chloride to the propargyl group of (XXXII) produced the butynamide derivative (XXXIII). The target triazole system (XXXIV) was obtained by dipolar cycloaddition of NaN3 to the acetylenic triple bond of (XXXIII) in hot DMSO. Finally, amide reduction in (XXXIV) with LiAlH4 led to the title dimethylaminomethyl triazole, which was isolated as the hydrochloride salt.
| 【1】 Baker, R.; Harrison, T.; Mcleod, A.M.; Owens, A.P.; Seward, E.M.; Swain, C.J.; Teall, M.R. (Merck Sharp & Dohme Ltd.); Substd. morpholine derivs. and their use as therapeutic agents. EP 0737192; EP 1099702; JP 1997507484; JP 2000219629; US 5612337; WO 9518124 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVIII) | 18293 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-([(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholine | 171482-05-6 | C20H18F7NO2 | 详情 | 详情 |
| (XXXI) | 11176 | 3-Bromopropyne; 3-Bromo-1-propyne | 106-96-7 | C3H3Br | 详情 | 详情 |
| (XXXII) | 53299 | (2R,3S)-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)-4-(2-propynyl)morpholine; (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)-4-(2-propynyl)morpholinyl ether | n/a | C23H20F7NO2 | 详情 | 详情 |
| (XXXIII) | 53300 | 4-[(2R,3S)-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)morpholinyl]-N,N-dimethyl-2-butynamide | n/a | C26H25F7N2O3 | 详情 | 详情 |
| (XXXIV) | 53301 | 4-{[(2R,3S)-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)morpholinyl]methyl}-N,N-dimethyl-1H-1,2,3-triazole-5-carboxamide | n/a | C26H26F7N5O3 | 详情 | 详情 |
合成路线5
Alternatively, morpholine (XVIII) was alkylated with 1,4-dichloro-2-butyne (XXXV) in the presence of K2CO3 to afford the propargyl chloride (XXXVI). Displacement of the chloride of (XXXVI) with sodium azide in DMSO gave the propargylic azide (XXXVII). The title triazole was then produced via isomerization and cyclization of azide (XXXVII) upon heating with dimethylamine in a sealed tube.
| 【1】 Harrison, T.; Owens, A.P.; Williams, B.J.; et al.; An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. J Med Chem 2001, 44, 24, 4296. |
| 【2】 Baker, R.; Harrison, T.; Mcleod, A.M.; Owens, A.P.; Seward, E.M.; Swain, C.J.; Teall, M.R. (Merck Sharp & Dohme Ltd.); Substd. morpholine derivs. and their use as therapeutic agents. EP 0737192; EP 1099702; JP 1997507484; JP 2000219629; US 5612337; WO 9518124 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVIII) | 18293 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-([(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholine | 171482-05-6 | C20H18F7NO2 | 详情 | 详情 |
| (XXXV) | 50923 | 1,4-Dichloro-2-butyne | 821-10-3 | C4H4Cl2 | 详情 | 详情 |
| (XXXVI) | 53302 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-4-(4-chloro-2-butynyl)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-(4-chloro-2-butynyl)-3-(4-fluorophenyl)morpholine | n/a | C24H21ClF7NO2 | 详情 | 详情 |
| (XXXVII) | 53303 | (2R,3S)-4-(4-azido-2-butynyl)-2-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-3-(4-fluorophenyl)morpholine; (2R,3S)-4-(4-azido-2-butynyl)-3-(4-fluorophenyl)morpholinyl (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether | n/a | C24H21F7N4O2 | 详情 | 详情 |
合成路线6
In a further method, the acetylide resulting from N,N-dimethyl propargylamine (XXXVIII) and either BuLi or ethylmagnesium chloride was formylated by means of N-methyl formanilide (XXXIX), producing the unstable acetylenic aldehyde (XL), which was immediately subjected to dipolar cycloaddition with sodium azide to furnish 4-(dimethylaminomethyl)-5-formyl-1,2,3-triazole (XLI). The title compound was then obtained by reductive condensation of morpholine (XVIII) with aldehyde (XLI) in the presence of sodium triacetoxyborohydride.
| 【1】 Wang, J.; Crocker, L.; Cai, D. (Merck & Co., Inc.); Polymorphic form of a tachykinin receptor antagonist. WO 0132656 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVIII) | 18293 | (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl (2R,3S)-3-(4-fluorophenyl)morpholinyl ether; (2R,3S)-2-([(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholine | 171482-05-6 | C20H18F7NO2 | 详情 | 详情 |
| (XXXVIII) | 53305 | 1-Dimethylamino-2-propyne; N,N-Dimethylpropargylamine | 7223-38-3 | C5H9N | 详情 | 详情 |
| (XXXIX) | 20360 | methyl(phenyl)formamide;N-Methylformanilide;N-Formyl-N-methylaniline;Methylphenylformamide;N-methyl-N-phenylformamide;N-Methyl-N-formylaniline;N-Formyl-N-methylaniline | 93-61-8 | C8H9NO | 详情 | 详情 |
| (XL) | 53304 | 4-(dimethylamino)-2-butynal | n/a | C6H9NO | 详情 | 详情 |
| (XLI) | 53306 | 5-[(dimethylamino)methyl]-1H-1,2,3-triazole-4-carbaldehyde | n/a | C6H10N4O | 详情 | 详情 |